Insulin is used medically to treat some forms of diabetes mellitus. Patients with type 1 diabetes mellitus depend on external insulin (most commonly injected subcutaneously) for their survival because the hormone is no longer produced internally. Those with type 2 diabetes mellitus are insulin-resistant, have relatively low insulin production, or both; certain patients with type 2 diabetes may eventually require insulin if other medications fail to control blood glucose levels adequately.
- 1 Principles
- 2 Types
- 3 Modes of administration
- 4 Dosage and timing
- 5 Dose calculation
- 6 Abuse
- 7 Detection in biological fluids
- 8 Insulin allergy
- 9 Combination with other antidiabetic drugs
- 10 History
- 11 References
|Amino Acid Sequence of Insulin Preparations|
|Amino Acid Substitutions|
Insulin is required for all animal life (excluding certain insects). Its mechanism of action is almost identical in nematode worms (e.g.C. elegans), fish, and mammals, and it is a protein that has been highly conserved across evolutionary time. Insulin must be administered to patients who experience such a deprivation. Clinically, this condition is called diabetes mellitus type 1.
The initial sources of insulin for clinical use in humans were cow, horse, pig or fish pancreases. Insulin from these sources is effective in humans as it is nearly identical to human insulin (three amino acid difference in bovine insulin, one amino acid difference in porcine). Differences in suitability of beef-, pork-, or fish-derived insulin for individual patients have historically been due to lower preparation purity resulting in allergic reactions to the presence of non-insulin substances. Though purity has improved steadily since the 1920s ultimately reaching purity of 99% by the mid-1970s thanks to high-pressure liquid chromatography (HPLC) methods, minor allergic reactions still occur occasionally, although the same types of allergic reactions have also been known to occur in response to synthetic "human" insulin varieties. Insulin production from animal pancreases was widespread for decades, but very few patients today rely on insulin from animal sources, largely because few pharmaceutical companies sell it anymore.
Biosynthetic "human" insulin is now manufactured for widespread clinical use using genetic engineering techniques using recombinant DNA technology, which the manufacturers claim reduces the presence of many impurities, although there is no clinical evidence to substantiate this claim. Eli Lilly marketed the first such insulin, Humulin, in 1982. Humulin was the first medication produced using modern genetic engineering techniques in which actual human DNA is inserted into a host cell (E. coli in this case). The host cells are then allowed to grow and reproduce normally, and due to the inserted human DNA, they produce a synthetic version of human insulin. However, the clinical preparations prepared from such insulins differ from endogenous human insulin in several important respects; an example is the absence of C-peptide which has in recent years been shown to have systemic effects itself. Genentech developed the technique Lilly used to produce Humulin, although the company never commercially marketed the product themselves.
Novo Nordisk has also developed a genetically engineered insulin independently using a yeast process. According to a survey that the International Diabetes Federation conducted in 2002 on the access to and availability of insulin in its member countries, approximately 70% of the insulin that is currently sold in the world is recombinant, biosynthetic 'human' insulin. A majority of insulin used clinically today is produced this way, although the clinical evidence has provided conflicting evidence on whether these insulins are any less likely to produce an allergic reaction. Adverse reactions have been reported, these include loss of warning signs that sufferers may slip into a coma through hypoglycemia, convulsions, memory lapse and loss of concentration. However, the International Diabetes Federation's position statement is very clear in stating that "there is NO overwhelming evidence to prefer one species of insulin over another" and "[modern, highly-purified] animal insulins remain a perfectly acceptable alternative."
Since January 2006, all insulins distributed in the U.S. and some other countries are synthetic "human" insulins or their analogues. A special FDA importation process is required to obtain bovine or porcine derived insulin for use in the U.S., although there may be some remaining stocks of porcine insulin made by Lilly in 2005 or earlier, and porcine insulin is also sold and marketed under the brand name Vetsulin(SM) in the U.S. for veterinary usage in the treatment of companion animals with diabetes. Wockhardt/
There are several problems with insulin as a clinical treatment for diabetes:
- Mode of administration.
- Selecting the 'right' dose and timing. Usually one unit of insulin is ~15grams of CHO.
- Selecting an appropriate insulin preparation (typically on 'speed of onset and duration of action' grounds).
- Adjusting dosage and timing to fit food intake timing, amounts, and types.
- Adjusting dosage and timing to fit exercise undertaken.
- Adjusting dosage, type, and timing to fit other conditions, for instance the increased stress of illness.
- Variability in absorption into the bloodstream via subcutaneous delivery
- The dosage is non-physiological in that a subcutaneous bolus dose of insulin alone is administered instead of combination of insulin and C-peptide being released gradually and directly into the portal vein.
- It is simply a nuisance for patients to inject whenever they eat carbohydrate or have a high blood glucose reading.
- It is dangerous in case of mistake (most especially 'too much' insulin).
Medical preparations of insulin (from the major suppliers – Eli Lilly, Novo Nordisk, and Sanofi Aventis – or from any other) are never just 'insulin in water'. Clinical insulins are specially prepared mixtures of insulin plus other substances including preservatives. These delay absorption of the insulin, adjust the pH of the solution to reduce reactions at the injection site, and so on.
Slight variations of the human insulin molecule are called insulin analogues, (technically "insulin receptor ligands") so named because they are not technically insulin, rather they are analogues which retain the hormone's glucose management functionality. They have absorption and activity characteristics not currently possible with subcutaneously injected insulin proper. They are either absorbed rapidly in an attempt to mimic real beta cell insulin (as with Lilly's lispro, Novo Nordisk's aspart and Sanofi Aventis' glulisine), or steadily absorbed after injection instead of having a 'peak' followed by a more or less rapid decline in insulin action (as with Novo Nordisk's version Insulin detemir and Sanofi Aventis's Insulin glargine), all while retaining insulin's glucose-lowering action in the human body. However, a number of meta-analyses, including those done by the Cochrane Collaboration in the United Kingdom in 2002, Germany's Institute for Quality and Cost Effectiveness in the Health Care Sector [IQWiG] released in 2007, and the Canadian Agency for Drugs and Technology in Health (CADTH) also released in 2007 have shown no unequivocal advantages in clinical use of insulin analogues over more conventional insulin types.
Choosing insulin type and dosage/timing should be done by an experienced medical professional working closely with the diabetic patient.
The commonly used types of insulin are:
- Fast-acting: Includes the insulin analogues aspart, lispro, and glulisine. These begin to work within 5 to 15 minutes and are active for 3 to 4 hours. Most insulins form hexamers which delay entry into the blood in active form; these analog insulins do not, but have normal insulin activity. Newer varieties are now pending regulatory approval in the U.S. which are designed to work rapidly, but retain the same genetic structure as regular human insulin.
- Short-acting: Includes regular insulin which begins working within 30 minutes and is active about 5 to 8 hours.
- Intermediate-acting: Includes NPH insulin which begins working in 1 to 3 hours and is active 16 to 24 hours.
- Long acting: Includes the analogues glargine and detemir, each of which begins working within 1 to 2 hours and continue to be active, without major peaks or dips, for about 24 hours, although this varies in many individuals.
- Ultra-long acting: Currently only includes the analogue degludec, which begins working within 30–90 minutes, and continues to be active for greater than 24 hours.
- Combination insulin products – Includes a combination of either fast-acting or short-acting insulin with a longer acting insulin, typically an NPH insulin. The combination products begin to work with the shorter acting insulin (5–15 minutes for fast-acting, and 30 minutes for short acting), and remain active for 16 to 24 hours. There are several variations with different proportions of the mixed insulins (e.g. Novolog Mix 70/30 contains 70% aspart protamine [akin to NPH], and 30% aspart.)
In late 2003, Wockhardt commenced manufacture of a yeast-based insulin costing $3.25 in India claiming it eliminated the risk of contracting diseases such as BSE and CJD associated with insulin derived from pigs and cattle. However, the company continues to manufacture insulin derived from pigs and cows in the United Kingdom under the Hypurin/CP Pharmaceuticals brand name.
Modes of administration
Unlike many medicines, insulin cannot be taken orally at the present time. Like nearly all other proteins introduced into the gastrointestinal tract, it is reduced to fragments (even single amino acid components), whereupon all 'insulin activity' is lost. There has been some research into ways to protect insulin from the digestive tract, so that it can be administered in a pill. So far this is entirely experimental.
Insulin is usually taken as subcutaneous injections by single-use syringes with needles, an insulin pump, or by repeated-use insulin pens with needles. Patients who wish to reduce repeated skin puncture of insulin injections often use an injection port in conjunction with syringes.
Administration schedules often attempt to mimic the physiologic secretion of insulin by the pancreas. Hence, both a long-acting insulin and a short-acting insulin are typically used.
Insulin pumps are a reasonable solution for some. Advantages to the patient are better control over background or 'basal' insulin dosage, bolus doses calculated to fractions of a unit, and calculators in the pump that may help with determining 'bolus' infusion dosages. The limitations are cost, the potential for hypoglycemic and hyperglycemic episodes, catheter problems, and no "closed loop" means of controlling insulin delivery based on current blood glucose levels.
Insulin pumps may be like 'electrical injectors' attached to a temporarily implanted catheter or cannula. Some who cannot achieve adequate glucose control by conventional (or jet) injection are able to do so with the appropriate pump.
As with injections, if too much insulin is delivered or the patient eats less than he or she dosed for, there will be hypoglycemia. On the other hand, if too little insulin is delivered, there will be hyperglycemia. Both can be life-threatening. In addition, indwelling catheters pose the risk of infection and ulceration, and some patients may also develop lipodystrophy due to the infusion sets. These risks can often be minimized by keeping infusion sites clean. Insulin pumps require care and effort to use correctly. However, some patients with diabetes are capable of keeping their glucose in reasonable control only with an insulin pump.
In 2006 the U.S. Food and Drug Administration approved the use of Exubera, the first inhalable insulin. It was withdrawn from the market by its maker as of third quarter 2007, due to lack of acceptance.
Inhaled insulin claimed to have similar efficacy to injected insulin, both in terms of controlling glucose levels and blood half-life. Currently, inhaled insulin is short acting and is typically taken before meals; an injection of long-acting insulin at night is often still required. When patients were switched from injected to inhaled insulin, no significant difference was observed in HbA1c levels over three months. Accurate dosing was a particular problem, although patients showed no significant weight gain or pulmonary function decline over the length of the trial, when compared to the baseline.
Following its commercial launch in 2005 in the UK, it was not (as of July 2006) recommended by National Institute for Health and Clinical Excellence for routine use, except in cases where there is "proven injection phobia diagnosed by a psychiatrist or psychologist".
In January 2008, the world's largest insulin manufacturer, Novo Nordisk A/S, also announced that the company was discontinuing all further development of the company's own version of inhalable insulin, known as the AERx iDMS inhaled insulin system. Similarly, Eli Lilly and Company ended its efforts to develop its inhaled Air Insulin in March 2008. However, MannKind Corp. (majority owner, Alfred E. Mann) remains optimistic about the concept.
There are several methods for transdermal delivery of insulin. Pulsatile insulin uses microjets to pulse insulin into the patient, mimicking the physiological secretions of insulin by the pancreas. Jet injection had different insulin delivery peaks and durations as compared to needle injection. Some diabetics find control possible with jet injectors, but not with hypodermic injection.
Both electricity using iontophoresis and ultrasound have been found to make the skin temporarily porous. The insulin administration aspect remains experimental, but the blood glucose test aspect of "wrist appliances" is commercially available.
Researchers have produced a watch-like device that tests for blood glucose levels through the skin and administers corrective doses of insulin through pores in the skin.
Intranasal insulin is being investigated. CPEX Pharmaceuticals reported phase 2a clinical trial preliminary results for its intranasal drug, Nasulin, on March 19, 2010; there's no word on when it might be expected on the market.
The basic appeal of oral hypoglycemic agents is that most people would prefer a pill to an injection. However, insulin is a protein, which is digested in the stomach and gut and in order to be effective at controlling blood sugar, cannot be taken orally in its current form.
The potential market for an oral form of insulin is assumed to be enormous, thus many laboratories have attempted to devise ways of moving enough intact insulin from the gut to the portal vein to have a measurable effect on blood sugar.
A number of derivatization and formulation strategies are currently being pursued to in an attempt to develop an orally available insulin. Many of these approaches employ nanoparticle delivery systems and several are being tested in clinical trials.
Another improvement would be a transplantation of the pancreas or beta cell to avoid periodic insulin administration. This would result in a self-regulating insulin source. Transplantation of an entire pancreas (as an individual organ) is difficult and relatively uncommon. It is often performed in conjunction with liver or kidney transplant, although it can be done by itself. It is also possible to do a transplantation of only the pancreatic beta cells. However, islet transplants had been highly experimental for many years, but some researchers in Alberta, Canada, have developed techniques with a high initial success rate (about 90% in one group). Nearly half of those who got an islet cell transplant were insulin-free one year after the operation; by the end of the second year that number drops to about one in seven. However, researchers at the University of Illinois at Chicago (UIC) have slightly modified the Edmonton Protocol procedure for islet cell transplantation and achieved insulin independence in diabetes patients with fewer but better-functioning pancreatic islet cells. Longer-term studies are needed to validate whether it improves the rate of insulin-independence.
Beta cell transplant may become practical in the near future. Additionally, some researchers have explored the possibility of transplanting genetically engineered non-beta cells to secrete insulin. Clinically testable results are far from realization at this time. Several other non-transplant methods of automatic insulin delivery are being developed in research labs, but none is close to clinical approval.
Dosage and timing
One international unit of insulin (1 IU) is defined as the "biological equivalent" of 34.7 μg pure crystalline insulin. This corresponds to the old USP insulin unit, where one unit (U) of insulin was set equal to the amount required to reduce the concentration of blood glucose in a fasting rabbit to 45 mg/dl (2.5 mmol/L).
The unit of measurement used in insulin therapy is not part of the International System of Units (abbreviated SI) which is the modern form of the metric system. Instead the pharmacological international unit (IU) is defined by the WHO Expert Committee on Biological Standardization.
The central problem for those requiring external insulin is picking the right dose of insulin and the right timing.
Physiological regulation of blood glucose, as in the non-diabetic, would be best. Increased blood glucose levels after a meal is a stimulus for prompt release of insulin from the pancreas. The increased insulin level causes glucose absorption and storage in cells, reduces glycogen to glucose conversion, reducing blood glucose levels, and so reducing insulin release. The result is that the blood glucose level rises somewhat after eating, and within an hour or so, returns to the normal 'fasting' level. Even the best diabetic treatment with synthetic human insulin or even insulin analogs, however administered, falls far short of normal glucose control in the non-diabetic.
Complicating matters is that the composition of the food eaten (see glycemic index) affects intestinal absorption rates. Glucose from some foods is absorbed more (or less) rapidly than the same amount of glucose in other foods. In addition, fats and proteins cause delays in absorption of glucose from carbohydrates eaten at the same time. As well, exercise reduces the need for insulin even when all other factors remain the same, since working muscle has some ability to take up glucose without the help of insulin.
Because of the complex and interacting factors, it is, in principle, impossible to know for certain how much insulin (and which type) is needed to 'cover' a particular meal to achieve a reasonable blood glucose level within an hour or two after eating. Non-diabetics' beta cells routinely and automatically manage this by continual glucose level monitoring and insulin release. All such decisions by a diabetic must be based on experience and training (i.e., at the direction of a physician, PA, or in some places a specialist diabetic educator) and, further, specifically based on the individual experience of the patient. But it is not straightforward and should never be done by habit or routine. With some care however, it can be done reasonably well in clinical practice. For example, some patients with diabetes require more insulin after drinking skim milk than they do after taking an equivalent amount of fat, protein, carbohydrate, and fluid in some other form. Their particular reaction to skimmed milk is different from other people with diabetes, but the same amount of whole milk is likely to cause a still different reaction even in that person. Whole milk contains considerable fat while skimmed milk has much less. It is a continual balancing act for all people with diabetes, especially for those taking insulin.
Patients with insulin-dependent diabetes typically require some base level of insulin (basal insulin), as well as short-acting insulin to cover meals (bolus insulin). Maintaining the basal rate and the bolus rate is a continuous balancing act that people with insulin-dependent diabetes must manage each day. This is normally achieved through regular blood tests, although continuous blood sugar testing equipment (Continuous Glucose Monitors or CGMs) are now becoming available which could help to refine this balancing act once widespread usage becomes common.
A long-acting insulin is used to approximate the basal secretion of insulin by the pancreas, which varies in the course of the day. NPH/isophane, lente, ultralente, glargine, and detemir may be used for this purpose. The advantage of NPH is its low cost, the fact that you can mix it with short-acting forms of insulin, thereby minimizing the number of injections that must be administered, and that the activity of NPH will peak 4–6 hours after administration, allowing a bedtime dose to balance the tendency of glucose to rise with the dawn, along with a smaller morning dose to balance the lower afternoon basal need and possibly an afternoon dose to cover evening need. A disadvantage of bedtime NPH is that if not taken late enough (near midnight) to place its peak shortly before dawn, it has the potential of causing hypoglycemia. The theoretical advantage of glargine and detemir, primarily for Type-2 patients, is that they only need to be administered once a day, although in practice many patients find that neither lasts a full 24 hours. They can be administered at any time during the day as well, provided that they are given at the same time every day. Glargine and detemir are significantly more expensive than NPH, lente and ultralente, and they cannot be mixed with other forms of insulin.
A short-acting insulin is used to simulate the endogenous insulin surge produced in anticipation of eating. Regular insulin, lispro, aspart and glulisine can be used for this purpose. Regular insulin should be given with about a 30 minute lead-time prior to the meal to be maximally effective and to minimize the possibility of hypoglycemia. Lispro, aspart and glulisine are approved for dosage with the first bite of the meal, and may even be effective if given after completing the meal. The short-acting insulin is also used to correct hyperglycemia.
The usual schedule for checking fingerstick blood glucose and administering insulin is before all meals and sometimes also at bedtime. More recent guidelines also call for a check 2 hours after a meal to ensure the meal has been 'covered' effectively.
What physicians typically refer to as sliding-scale insulin is fast- or rapid-acting insulin only, given subcutaneously, typically at meal times and sometimes bedtime, but only when blood glucose is above a threshold, usually 10 mmol/L. No basal insulin is given, usually resulting in an elevated blood glucose each morning, which is then chased throughout the day, with the cycle repeated the next day.
Insulin prescriptions generally specify fixed amounts of long-acting insulin to be given routinely, and fixed amounts of short-acting insulin prior to every meal (the 'sliding scale' approach). However, the amount of short-acting insulin may be varied depending on the patient's preprandial fingerstick glucose, in order to correct pre-existing hyperglycemia. The so-called "sliding-scale" is still widely taught, although it is controversial. It was first described in 1934.
|before breakfast||before lunch||before dinner||at bedtime|
|NPH dose||12 units||6 units|
|regular insulin dose if fingerstick
glucose is (mg/dl) [mmol/L]:
|70-100 [3.9-5.5]||4 units||4 units|
|101-150 [5.6-8.3]||5 units||5 units|
|151-200 [8.4-11.1]||6 units||6 units|
|201-250 [11.2-13.9]||7 units||7 units|
|251-300 [14.0-16.7]||8 units||1 unit||8 units||1 unit|
|>300 [>16.7]||9 units||2 units||9 units||2 units|
Sample regimen using insulin glargine and insulin lispro:
- Insulin glargine: 20 units at bedtime
|if fingerstick glucose
is (mg/dl) [mmol/L]:
|before breakfast||before lunch||before dinner||at bedtime|
|70-100 [3.9-5.5]||5 units||5 units||5 units|
|101-150 [5.6-8.3]||6 units||6 units||6 units|
|151-200 [8.4-11.1]||7 units||7 units||7 units|
|201-250 [11.2-13.9]||8 units||8 units||8 units||1 unit|
|251-300 [14.0-16.7]||9 units||9 units||9 units||2 units|
|>300 [>16.7]||10 units||10 units||10 units||3 units|
Carb counting and DAFNE
A more complicated method that allows greater freedom with meal times and snacks is "carb counting." This approach is taught to diabetic patients in the UK and elsewhere as "Dose Adjustment For Normal Eating" or DAFNE.
In Europe, patients who are not familiar with the DAFNE regime can take an educational course where the basic starting insulin dose guideline is "for every 10g of carbohydrates you eat, take 1 unit of insulin". DAFNE courses also cover topics that naturally work alongside this regime, such as blood glucose monitoring, exercise and carbohydrate estimation to help the patient work out their personal control requirements.
Patients can also use their total daily dose (TDD) of insulin to estimate how many grams of carbohydrates will be "covered" by 1 unit of insulin, and using this result, estimate how many units of insulin should be administered depending on the carbohydrate content of their meal. For example, if the patient determines that 1 unit of insulin will cover 15 grams of carbohydrates, then they must administer 5 units of insulin before consuming a meal that contains 75 grams of carbohydrates.
Some alternative methods also consider the protein content of the meal (since excess dietary protein can be converted to glucose via gluconeogenesis).
With DAFNE, most dosages involve a fair degree of guesswork, especially with non-labeled foods, and will only work fairly consistently from one dosage to the next if the patient is aware of their body's requirements. For example, a patient finds they can take 1 unit to 10g of carbohydrates in the morning and the evening, but find that their body requires more insulin for a meal in the middle of the day so they have to adjust to 1 unit per 8.5g of carbohydrates.
Other less obvious factors that affect the body's use of insulin must also be taken into account. For example, some patients may find that their bodies process insulin better on hot days so require less insulin. With this, the patient again has to adjust their dose to the best of their understanding from their past experiences.
The DAFNE regime requires the patient to learn about their body's needs through experience, which takes time and patience, but it can then become effective.
Closed-loop predictive modeling
Patients with fluctuating insulin requirements may benefit from a closed-loop predictive modeling approach. As an extension on "carb counting", in this closed-loop predictive modeling approach, the four daily insulin dosages needed to reach the target blood sugar levels for the “normal” daily carbohydrate consumption and amount of physical activity, are continuously adjusted based on the pre-meal and pre-night blood sugar level readings. Each new blood sugar reading provides the feedback to fine-tune and track the body’s insulin requirements. Within this strategy the key patient specific factors, which have to be determined experimentally, are the blood sugar correction factor and the carbohydrate ratio. The blood sugar correction factor sets both the “proportional gain” and “integral gain” factors for the four feedback loops. When taken too low, deviations from the target blood sugar level are not corrected for effectively, when taken too high, the blood sugar regulation will become unstable. Since in this approach, the carbohydrate ratio is only used to account for non-standard carbohydrate intakes, it is usually not required to work with meal specific ratios.
Proper modeling of the amount of insulin remaining to act in the patient’s body is essential in this strategy, for instance to ensure that any adjustment in the amount of basal insulin is accounted for when calculating the bolus amounts needed for the meals. Due to the need to account for each insulin’s activity profile, analyze past blood sugar trends, and to factor in non-standard carbohydrate intakes and exercise levels, this strategy requires a dedicated smartphone application to handle all the calculations, and to return meaningful dosing recommendations and expected blood sugar levels.
Dietary control of insulin
Many popular weight-loss regimes claim to manipulate weight gain forcing insulin levels (often characterized as insulin overload) by control of carbohydrate intake. Insulin release is controlled by several factors; the carbohydrate stimulus is blood glucose which is not produced by all kinds of carbohydrate. Some types of amino acids also stimulate insulin release. In addition, overly high levels of insulin are seen only in those with pathologies such as Type 2 diabetes mellitus, and only in some of those. The typical person cannot have insulin overload and still have blood glucose levels which do not force symptoms of hypoglycemia. In the non-diabetic, the feedback control mechanism connecting insulin release and blood glucose level is very effective, and it is not possible to adjust it except that blood glucose levels rise slightly during digestion and absorption of glucose. The decrease in blood glucose levels is directly attributable to release of insulin, and that release ceases as blood glucose levels drop. On the other hand, prolonged abnormally low levels of insulin, if it were possible to produce them by control of diet composition and amount, would produce problems with electrolyte balance and with amino acid uptake in cells, among many other effects.
- TR = target rate
- CF = corrective factor
- KF = carbohydrate factor
Blood glucose and target rate are expressed in mg/dL or mmol/L. Constants should be set by a physician.
There are reports that some abuse insulin by injecting large doses that lead to hypoglycemic states. This is extremely dangerous. Severe acute or prolonged hypoglycemia can result in brain damage or death.
On July 23, 2004, news reports claimed that a former spouse of a prominent international track athlete said that the ex-spouse had used insulin as a way of 'energizing' the body. There is no evidence to suggest it should act as a performance enhancer in non-diabetics. Poorly controlled diabetics are more prone than others to exhaustion and tiredness, and properly-administered insulin can relieve such symptoms.
Game of Shadows, by reporters Mark Fainaru-Wada and Lance Williams, includes allegations that Barry Bonds used insulin in the apparent belief that it would increase the effectiveness of the growth hormone he was alleged to be taking. On top of this, non-prescribed insulin is a banned drug at the Olympics and other global competitions.
The use and abuse of exogenous insulin is claimed to be widespread amongst the bodybuilding community. Insulin, human growth hormone (HGH) and insulin-like growth factor 1 (IGF-1) are self-administered by those looking to increase muscle mass beyond the scope offered by anabolic steroids alone. Their rationale is that since insulin and HGH act synergistically to promote growth, and since IGF-1 is a primary mediator of musculoskeletal growth, the 'stacking' of insulin, HGH and IGF-1 should offer a synergistic growth effect on skeletal muscle. This theory has been supported in recent years by top-level bodybuilders whose competition weight is in excess of 50 lb (23 kg) of muscle, larger than that of competitors in the past, and with even lower levels of body fat. There has even been some reaction to the 'freakish' appearance of some of today's top-level professionals.
Bodybuilders are claimed to inject up to 10 IU of quick-acting synthetic insulin following meals containing starchy carbohydrates and protein, but little fat, in an attempt to "force feed" muscle cells with nutrients necessary for growth, whilst preventing growth of adipocytes (i.e., fat cells). This may be done up to four times each day, following meals, for a total usage of perhaps 40 IU of synthetic insulin per day. However, there have been reports of substantially heavier usage, amongst even "recreational" bodybuilders.
The abuse of exogenous insulin carries with it an attendant risk of hypoglycemic coma and death when the amount used is in excess of that required to handle ingested carbohydrate. Acute risks include brain damage, paralysis, and death. Long-term risks may include development of type 2 diabetes and, potentially, a lifetime dependency on exogenous insulin. However, no studies have been conducted showing that exogenous insulin abuse may lead to increased risk of type 2 diabetes.
Detection in biological fluids
Insulin is often measured in serum, plasma or blood in order to monitor therapy in diabetic patients, confirm a diagnosis of poisoning in hospitalized persons or assist in a medicolegal investigation of suspicious death. Interpretation of the resulting insulin concentrations is complex, given the numerous types of insulin available, various routes of administration, the presence of anti-insulin antibodies in insulin-dependent diabetics and the ex vivo instability of the drug. Other potential confounding factors include the wide-ranging cross-reactivity of commercial insulin immunoassays for the biosynthetic insulin analogs, the use of high-dose intravenous insulin as an antidote to antihypertensive drug overdosage and postmortem redistribution of insulin within the body. The use of a chromatographic technique for insulin assay may be preferable to immunoassay in some circumstances, to avoid the issue of cross-reactivity affecting the quantitative result and also to assist identifying the specific type of insulin in the specimen.
Allergy to Insulin products is rare with a prevalence of about 2%, of which most reactions are not due to the Insulin itself but to preservatives added to insulin such as zinc, protamine, and meta-cresol. Most reactions are Type I hypersensitivity reactions and rarely cause anaphylaxis. A suspected allergy to Insulin can be confirmed by skin prick testing, patch testing and occasionally skin biopsy. First line therapy against Insulin hypersensitivity reactions include symptomatic therapy with antihistamines. The affected persons are then switched to a preparation that does not contain the specific agent they are reacting to or undergo desensitization.
Combination with other antidiabetic drugs
A combination therapy of insulin and other antidiabetic drugs appears to be most beneficial in diabetic patients who still have residual insulin secretory capacity. A combination of insulin therapy and sulphonylurea is more effective than insulin alone in treating patients with type 2 diabetes after secondary failure to oral drugs, leading to better glucose profiles and/or decreased insulin needs.
- 1922 Frederick Banting, Charles Best and James Collip use bovine insulin extract in humans in Toronto, Canada.
- 1922 Leonard Thompson and then Elizabeth Hughes Gossett (daughter of a former New York State governor and 1916 U.S. Republican presidential candidate) are treated in Toronto
- 1923 Eli Lilly produces commercial quantities of much purer bovine insulin than Banting et al. had used
- 1923 Farbwerke Hoechst, one of the forerunner's of today's Sanofi Aventis, produces commercial quantities of bovine insulin in Germany
- 1923 Hagedorn founds the Nordisk Insulinlaboratorium in Denmark – forerunner of today's Novo Nordisk
- 1926 Nordisk receives a Danish charter to produce insulin as a non-profit
- 1936 Canadians D.M. Scott, A.M. Fisher formulate a zinc insulin mixture and license it to Novo
- 1936 Hagedorn discovers that adding protamine to insulin prolongs the duration of action of insulin
- 1946 Nordisk formulates Isophane porcine insulin aka Neutral Protamine Hagedorn or NPH insulin
- 1946 Nordisk crystallizes a protamine and insulin mixture
- 1950 Nordisk markets NPH insulin
- 1953 Novo formulates Lente porcine and bovine insulins by adding zinc for longer lasting insulin
- 1955 Frederick Sanger determines the amino acid sequence of insulin
- 1966 Synthesized by total synthesis by C.L. Tsou, Wang Yinglai, and coworkers
- 1969 Dorothy Crowfoot Hodgkin solves the crystal structure of insulin by x-ray crystallography
- 1973 Purified monocomponent (MC) insulin is introduced
- 1973 The U.S. officially "standardized" insulin sold for human use in the U.S. to U-100 (100 units per milliliter). Prior to that, insulin was sold in different strengths, including U-80 (80 units per milliliter) and U-40 formulations (40 units per milliliter), so the effort to "standardize" the potency aimed to reduce dosage errors and ease doctors' job of prescribing insulin for patients. Other countries also followed suit.
- 1978 Genentech produces biosynthetic 'human' insulin in Escherichia coli bacteria using recombinant DNA techniques, licenses to Eli Lilly
- 1981 Novo Nordisk chemically and enzymatically converts porcine to 'human' insulin
- 1982 Genentech synthetic 'human' insulin (above) approved
- 1983 Eli Lilly and Company produces biosynthetic 'human' insulin with recombinant DNA technology, Humulin
- 1985 Axel Ullrich sequences a human cell membrane insulin receptor.
- 1988 Novo Nordisk produces recombinant biosynthetic 'human' insulin
- 1996 Lilly Humalog "lispro" insulin analogue approved.
- 2000 Sanofi Aventis Lantus insulin "glargine" analogue approved for clinical use in the US and Europe.
- 2004 Sanofi Aventis Apidra insulin "glulisine" insulin analogue approved for clinical use in the US.
- 2006 Novo Nordisk Levemir "detemir" insulin analogue approved for clinical use in the US.
- Takiya, Lisa, Dougherty, Tanya. "Pharmacist's Guide to Insulin Preparations: A Comprehensive Review". Pharmacy Times. Retrieved 2 August 2010.
- Nasrallah, Sami; L. Raymond Reynolds, (1 April 2012). "Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?". Clinical Medicine Insights: Endocrinology and Diabetes 5: 31–7. doi:10.4137/CMED.S9494. PMC 3411522. PMID 22879797. Retrieved 16 November 2012.
- Novolog Patient Leaflet
- IDF (2004). Diabetes Atlas,: 2nd ed. International Diabetes Federation, Brussels.
- Paul Brown (March 9, 1999). "Diabetics not told of insulin risk". Guardian.
- IDF March 2005; "Position Statement." International Diabetes Federation, Brussels.
- Vetsulin-Veterinary Overview
- Insulin Dependent Diabetes Trust-HealthCanada Licenses Hypurin Pork Insulins
- Richter B, Neises G (2002). "'Human' insulin versus animal insulin in people with diabetes mellitus". Cochrane Database Syst Rev (3): CD003816. doi:10.1002/14651858.CD003816. PMID 12137720.
- IQwiG (German Institute for Quality and Efficiency in Health Care) (6 June 2007). "Rapid-acting insulin analogues in the treatment of diabetes mellitus type 1: Superiority Not Proven". Retrieved 2 August 2010.
- Banerjee S, Tran K, Li H, Cimon K, Daneman D, Simpson S, Campbell K (2007). "Short-acting insulin analogues for diabetes mellitus: meta-analysis of clinical outcomes and assessment of cost effectiveness". Canadian Agency for Drugs and Technologies in Health 87.
- Biodel Inc. Announces VIAject(TM) Data at Oral Presentation at the American Diabetes Association Meeting
- FDA Accepts VIAject NDA for Review
- "Indian firm markets vegetarian insulin". BBC News. August 5, 2003. Retrieved May 5, 2010.
- Insulin in the UK-Diabetes.co.uk
- FDA approval of Exubera inhaled insulin
- NICE (June 21, 2006). "Diabetes (type 1 and 2), Inhaled Insulin - Appraisal Consultation Document (second)". Retrieved 2006-07-26.
- Cefalu W, Skyler J, Kourides I, Landschulz W, Balagtas C, Cheng S, Gelfand R (2001). "Inhaled human insulin treatment in patients with type 2 diabetes mellitus". Ann Intern Med 134 (3): 203–7. doi:10.7326/0003-4819-134-3-200102060-00011. PMID 11177333.
- Novo Nordisk refocuses its activities within inhaled insulin and discontinues the development of AERx
- Lilly Ends Effort to Develop an Inhaled Insulin Product
- Pollack, Andrew. "Betting an Estate on Inhaled Insulin", The New York Times, 16 Nov 2007., are still proceeding with their own inhaled insulin plans.
- Arora A, Hakim I, Baxter J, Rathnasingham R, Srinivasan R, Fletcher DA, Mitragotri S (March 2007). "Needle-free delivery of macromolecules across the skin by nanoliter-volume pulsed microjets". Proc. Natl. Acad. Sci. U.S.A. 104 (11): 4255–60. doi:10.1073/pnas.0700182104. PMC 1838589. PMID 17360511.
- Dixit N, Bali V, Baboota S, Ahuja A, Ali J (January 2007). "Iontophoresis - an approach for controlled drug delivery: a review". Curr Drug Deliv 4 (1): 1–10. doi:10.2174/156720107779314802. PMID 17269912.
- Lalej-Bennis D, Boillot J, Bardin C, Zirinis P, Coste A, Escudier E, Chast F, Peynegre R, Selam JL, Slama G (August 2001). "Efficacy and tolerance of intranasal insulin administered during 4 months in severely hyperglycaemic Type 2 diabetic patients with oral drug failure: a cross-over study". Diabet. Med. 18 (8): 614–8. doi:10.1046/j.1464-5491.2001.00528.x. PMID 11553197.
- CPEX Pharmaceuticals Announces Preliminary Results From Its Phase 2a Clinical Trial Of Nasulin
- "Oral Insulin - Fact or Fiction? - Resonance - May 2003". Retrieved 2007-09-23.
- Kalra S, Kalra B, Agrawal N (2010). "Oral insulin". Diabetol Metab Syndr 2: 66. doi:10.1186/1758-5996-2-66. PMC 2987915. PMID 21059246.
- Card JW, Magnuson BA (December 2011). "A review of the efficacy and safety of nanoparticle-based oral insulin delivery systems". Am. J. Physiol. Gastrointest. Liver Physiol. 301 (6): G956–67. doi:10.1152/ajpgi.00107.2011. PMID 21921287.
- Chen MC, Sonaje K, Chen KJ, Sung HW (December 2011). "A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery". Biomaterials 32 (36): 9826–38. doi:10.1016/j.biomaterials.2011.08.087. PMID 21925726.
- Fonte P, Araújo F, Reis S, Sarmento B (2013). "Oral insulin delivery: how far are we?". J Diabetes Sci Technol 7 (2): 520–31. doi:10.1177/193229681300700228. PMC 3737653. PMID 23567010.
- Iyer H, Khedkar A, Verma M (March 2010). "Oral insulin - a review of current status". Diabetes Obes Metab 12 (3): 179–85. doi:10.1111/j.1463-1326.2009.01150.x. PMID 20151994.
- Gangemi A, Salehi P, Hatipoglu B, Martellotto J, Barbaro B, Kuechle JB, Qi M, Wang Y, Pallan P, Owens C, Bui J, West D, Kaplan B, Benedetti E, Oberholzer J (June 2008). "Islet transplantation for brittle type 1 diabetes: the UIC protocol". Am. J. Transplant. 8 (6): 1250–61. doi:10.1111/j.1600-6143.2008.02234.x. PMID 18444920.
- Zhu YL, Abdo A, Gesmonde JF, Zawalich KC, Zawalich W, Dannies PS (August 2004). "Aggregation and lack of secretion of most newly synthesized proinsulin in non-beta-cell lines". Endocrinology 145 (8): 3840–9. doi:10.1210/en.2003-1512. PMID 15117881.
- Mission statement from: WHO Expert Committee on Biological Standardization
- Scheiner, Gary; Boyer BA (Jul 2005). "Characteristics of basal insulin requirements by age and gender in Type-1 diabetes patients using insulin pump therapy". Diabetes Res Clin Pract 69 (1): 14–21. doi:10.1016/j.diabres.2004.11.005. PMID 15955383.
- Dawn phenomenon
- Umpierrez GE, Palacio A, Smiley D (2007). "Sliding scale insulin use: myth or insanity?". Am J Med 120 (7): 563–7. doi:10.1016/j.amjmed.2006.05.070. PMID 17602924.
- Hirsch, Irl (January 14, 2009). "Sliding Scale Insulin - Time to Stop Sliding". The Journal of the American Medical Association 301 (2): 213–214. doi:10.1001/jama.2008.943.
- Joslin EP (1934). A Diabetic Manual for the Mutual Use of Doctor and Patient. Philadelphia, PA: Lea & Febiger. p. 108.
- R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 775-779.
- Ghazavi, MK; Johnston, GA (May–Jun 2011). "Insulin allergy.". Clinics in dermatology 29 (3): 300–5. PMID 21496738.
- Scheen AJ, Castillo MJ, Lefèbvre PJ (1993). "Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes". Acta Clin. Belg. 48 (4): 259–268. PMID 8212978.
- Abigail Zuger (October 4, 2010). "Rediscovering the First Miracle Drug". New York Times. Retrieved 2010-10-06. "But not Elizabeth Hughes: she ran in the other direction, far from the headlines that briefly made her the most famous diabetic child in the United States. Although she received an estimated 42,000 insulin shots before she died in 1981 at the age of 74, she systematically destroyed most of the material documenting her illness, expunged all references to diabetes from her father’s papers, and occasionally even denied she had been ill as a child."